Search Results

You are looking at 41 - 50 of 71 items for :

Clear All
Full access

Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff and Hannah M. Linden

colony-stimulating factor (G-CSF) for more than 30 days before image T4. At T1, the arrow shows spinal metastasis at L1 with strong uptake by FDG-PET (left, A, maximum standard uptake value [SUV] 6.1) and FES-PET (right, B, maximum SUV 8.3). The patient

Full access

Donna Trauth and Lori J. Goldstein

/doxorubicin followed by Taxol as adjuvant systemic chemotherapy for node-positive breast cancer (CALGB 9141): Randomized comparison of two dose levels of G-CSF (Abstr. #63) . Proc Am Soc Clin Oncol 1994 ; 13 : 65 . 64 Henderson IC Berry D Demetri G

Full access

Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma and Dorothy A. Shead

colony-stimulating factor (G-CSF) responsiveness in predicting the occurrence of infections in patients with hematologic malignancies undergoing high-dose therapy and autologous HSCT. 68 Responsiveness to G-CSF was determined by the administration of a

Full access

Tanya M. Wildes, Derek L. Stirewalt, Bruno Medeiros and Arti Hurria

and non-Hodgkin’s lymphoma: survey from a single institution . Am J Hematol 2003 ; 73 : 267 – 272 . 13. Micallef IN Stiff PJ Stadtmauer EA . Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34

Full access

Dawn Goetz

with neutrophil counts of 1500 cells/mm 3 or lower. In addition, primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is recommended in high-risk patients. A dose reduction to 20 mg/m 2 may be considered for patients who experience

Full access

Thomas A. Cumbo and Brahm H. Segal

Price TH Bowden RA Boeckh M . Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoeitic stem cell transplantation . Blood 2000 ; 95 : 3302 – 3309

Full access

Jeffrey E. Lancet and Sergio Giralt

-infusion, high-dose cytosine arabinoside . Blood 2002 ; 99 : 4343 – 4349 . 42. Fianchi L Pagano L Leoni F . Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute

Full access

Taofeek K. Owonikoko and Suresh Ramalingam

. 30. Okamoto H Naoki K Narita Y . A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer . Lung Cancer 2006 ; 53 : 197 – 203

Full access

H. Joachim Deeg and Marcos de Lima

-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF) . Cytokines Mol Ther 1995 ; 1 : 21 – 28 . 34. Platzbecker U Schetelig J Finke J . Allogeneic hematopoietic cell transplantation in

Full access

Arjan A. van de Loosdrecht and Theresia M. Westers

. Haematologica 2007 ; 92 : 859 – 860 . 39. Sconocchia G Fujiwara H Rezvani K . G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte . J Leukoc Biol 2004 ; 76 : 1214 – 1219 . 40